Get started
Author

José L. Blaya-Cánovas

Antioxidants for the Treatment of Breast Cancer: Are We There Yet?
2021 · Carmen Griñan-Lison, Jose L. Blaya-Cánovas, et al. · Antioxidants · 98
Drug Repurposing for Triple-Negative Breast Cancer
2020 · Marta Ávalos-Moreno, Araceli López-Tejada, et al. · Journal of Personalized Medicine · 54
PDF
TGFβ Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression
2022 · Araceli López-Tejada, Carmen Griñán-Lisón, et al. · International Journal of Biological Sciences · 17
PDF
Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer
2022 · Alba Navarro-Ocón, Jose L. Blaya-Cánovas, et al. · Pharmaceutics · 17
Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy
2024 · José L. Blaya-Cánovas, Carmen Griñán-Lisón, et al. · Molecular Cancer · 16
Unlocking the effective alliance of β-lapachone and hydroxytyrosol against triple-negative breast cancer cells
2024 · Jesús Calahorra, José L. Blaya-Cánovas, et al. · Biomedicine & Pharmacotherapy · 13
Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy
2025 · Violeta Delgado-Almenta, Jose L. Blaya-Cánovas, et al. · Pharmaceutics · 9
PDF
Signature-based repurposed drugs resemble the inhibition of TGFβ-induced NDRG1 as potential therapeutics for triple-negative breast cancer
2025 · Araceli López-Tejada, Jose L. Blaya-Cánovas, et al. · International Journal of Biological Sciences · 4
PDF
Works count: 13
Citation count: 228
H-index: 7
I10-index: 6
Year
Topic
Type